Synovio Therapeutics
Drug Candidate for Osteoarthritis Therapy
Active
Pre-Seed
Startup
Founded 2025-01
Synovio Therapeutics develops a novel small molecule, Fenchone 1D, a specific agonist to the CB2 receptor as a drug candidate for Osteoarthritis therapy.
SectorHealth Tech & Life Sciences
StagePre-Seed
Employees1
Founded2025-01
Confidence58
Sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals